This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Post Exposure Treatment With Doxycycline for the Prevention of Relapsing Fever

This study has been completed.
Information provided by:
Medical Corps, Israel Defense Force Identifier:
First received: October 7, 2005
Last updated: October 23, 2008
Last verified: April 2003

Abstract Background Tick-Borne Relapsing Fever (TBRF) is an acute febrile illness. In Israel, TBRF is caused by Borrelia persica and is transmitted by Ornithodoros tholozani ticks. We examined the safety and efficacy of a post exposure treatment policy to prevent TBRF.

Methods In a double blind, placebo controlled trial 93 healthy volunteers with suspected tick exposure (51 with bite signs and 42 contacts) were randomly assigned to receive either Doxycycline (200 mg for the first day and 100mg/d for 4 days) or placebo, approximately 2 days after contact. Blood smears were examined for Borrelia at inclusion and during fever rise. Serology for Lyme disease cross- reactivity and PCR for Borrelia GlpQ gene were also performed. Cases of TBRF were defined as subjects having fever and a positive blood smear.

Condition Intervention Phase
Relapsing Fever, Tick-Borne Jarisch Herxheimer Reaction Drug: doxycycline treatment Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Official Title: Post Exposure Treatment With Doxycycline for the Prevention of Relapsing Fever

Resource links provided by NLM:

Further study details as provided by Medical Corps, Israel Defense Force:

Estimated Enrollment: 140
Study Start Date: April 2002
Estimated Study Completion Date: April 2003

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • suspected exposure to tick-borne relapsing fever
  • after returning from field exercise in a tick-borne relapsing fever infected area
  • having a tick bite or staying in field in close proximity to a subject with tick bite sign

Exclusion Criteria:

  • known sensitivity to tetracycline or doxycycline
  • febrile illness on recruitment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00237016

Israel Defence Forces
Tel Hashomer, Israel
Sponsors and Collaborators
Medical Corps, Israel Defense Force
Principal Investigator: Tal Hasin, MD Medical corps, Israel Defence Forces
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00237016     History of Changes
Other Study ID Numbers: RF1
Study First Received: October 7, 2005
Last Updated: October 23, 2008

Additional relevant MeSH terms:
Relapsing Fever
Body Temperature Changes
Signs and Symptoms
Borrelia Infections
Gram-Negative Bacterial Infections
Bacterial Infections
Tick-Borne Diseases
Spirochaetales Infections
Anti-Bacterial Agents
Anti-Infective Agents
Antiprotozoal Agents
Antiparasitic Agents processed this record on August 18, 2017